Citations

Clear

2960 citation(s) found for "Kim, P".

Factors Affecting Accreditation in Extracranial Carotid Ultrasound Studies by the Intersocietal Accreditation Commission
Polak, Joseph F. , Dahiya, Nirvikar , Go, Michael R. , Kim, Esther S.H. , Kundu, Sanjoy, Yesenko, Sandra , Hutchisson, Marge

Mayo Clinic

Journal for Vascular Ultrasound | October 10, 2025 | Volume: 49 | Issue: 3 | Pages: 123-127

10.1177/15443167251376345 Get It

Introduction: Accreditation of vascular laboratories has been shown to lead to overall improvements in quality patient care. However, there are still factors that needlessly delay the granting of full accreditation. We performed a retrospective analysis looking at factors associated with delays in accreditation in extracranial carotid artery ultrasound examinations by the Intersocietal Accreditation Commission - Vascular Testing (IAC-VT) division. Materials and Methods: We accessed an active database from the IAC-VT division between 2014 and 2020 and extracted data linked to vascular laboratory accreditation in extracranial carotid ultrasound studies. We used the ‘Delay” versus the “Grant” status as outcome and looked at the association with 18 metrics that are part of the application evaluation. We further used a modified Delphi method to determine the relative role played by either the technologist/sonographer or the interpreting physician for each metric. Statistical significance was evaluated by Chi-square. Results: A “Delay” status was assigned in 1638 (58.6%) out of 2794. Ten factors were noted to be significant univariate predictors of a “Delay” status. The three major factors were solely associated with the interpreting physician while adherence to technical factors showed mostly shared responsibility. Conclusion: This retrospective study indicated that the accreditation process is strongly dependent on interpreting physician performance. Targeted interventions may help decrease time and effort associated with the costs of the accreditation process.
Investigation of DNA Damage Response Genes Validates the Role of DNA Repair in Pediatric Cancer Risk and Identifies SMARCAL1 as a Novel Osteosarcoma Predisposition Gene
Oak, Ninad , Chen, Wenan , Blake, Alise K. , Harrison, Lynn , O’Brien, Martha A., Previti, Christopher , Balasubramanian, Gnanaprakash, Hirsch, Steffen , Penkert, Judith , Jones, Barbara C. , Schramm, Kathrin , Nathrath, Michaela , Witt, Olaf , Li, Jiaming , Ness, Kirsten K. , Kratz, Christian P. , Armstrong, Greg , Autry, Robert J. , Nichols, Kim E. , Armstrong, Gregory T. , Blake, Alise , Hirsch, Steffen , Penkert, Judith , Jones, Barbara C , Nathrath, Michaela , Pajtler, Kristian W , Jones, David T W , Witt, Olaf , Dirksen, Uta , Li, Jiaming , Sapkota, Yadav , Ness, Kirsten K , Guenther, Lillian M , Kratz, Christian , Wang, Zhaoming , Hudson, Melissa M , Wu, Gang , Nichols, Kim E , Sharma, Richa , O'Brien, Martha, Maaß, Kendra K. , Pajtler, Kristian W. , Jones, David , Sapkota, Yadav , Pfister, Stefan M. , Wang, Zhaoming , Hudson, Melissa M. , Wu, Gang , Sharma, Richa

Mayo Clinic

Journal of Clinical Oncology | October 9, 2025 | Volume: 43 | Issue: 36 | Pages: 3833-3843

10.1200/jco-25-01114 | PMID 41066719 Get It

PURPOSE Recent studies reveal that 5%-18% of children with cancer harbor pathogenic variants in known cancer-predisposing genes. However, DNA damage repair (DDR) genes, which are frequently somatically altered in pediatric tumors, have not been systematically examined as a source of novel cancer-predisposing signals. METHODS To address this gap, we interrogated 189 DDR genes for presence of germline predisposing variants (PV) among 5,993 childhood cancer cases and 14,477 adult noncancer controls (discovery cohort). PV were determined using a tiered approach incorporating ClinVar annotations, InterVar classification, and in silico tools (REVEL, CADD, and MetaSVM). Using logistic and firth regression, we identified genes with PV statistically enriched in the germline of children with tumors and replicated findings among 1,497 additional childhood cancer cases across three independent cohorts. RESULTS Analysis across all cases with cancer revealed enrichment of TP53 PV. Cancer-specific analyses confirmed known associations including germline TP53 PV in adrenocortical carcinoma, high-grade glioma (HGG), and medulloblastoma (MB), PMS2 in HGG and non-Hodgkin lymphoma (NHL), MLH1 in HGG, BRCA2 in NHL, and BARD1 in neuroblastoma. In addition, four novel associations were uncovered, including BRCA1 in ependymoma, SPIDR in HGG, SMC5 in MB, and SMARCAL1 in osteosarcoma (OS). Importantly, the SMARCAL1 :OS association was significant in the discovery (6/230, 2.6%, false discovery rate [FDR] logistic = 0.0189) as well as all three replication cohorts (Childhood Cancer Survivor Study: 8/275, 2.9%; P Fisher < .0001; Cancer Predisposition Syndrome-German Childhood Cancer Registry: 4/135, 3%, P Fisher = .002; Individualized Therapy for Relapsed Malignancies in Childhood: 4/217, 1.8%, P Fisher = .012). The remaining wild-type SMARCAL1 allele was deleted in three of four OS tumors with available data. CONCLUSION Our study confirms the relevance DDR genetic variation in pediatric cancer risk and establishes SMARCAL1 as a novel OS predisposing gene, providing insights into tumor biology and creating opportunities to optimize care for patients with this challenging tumor.
Risk of Future Hemorrhage From Unruptured Brain Arteriovenous Malformations
Kim, Helen , Nelson, Jeffrey , Hess, Christopher, Lanzino, Giuseppe, Koroknay-Pál, Päivi , Oulasvirta, Elias, Laakso, Aki , Lawton, Michael T., Mohr, J.P. , Morgan, Michael K. , Moayeri, Nicole, Zaroff, Jonathan G. , Chen, Xiaolin , Zhao, Yuanli , Flemming, Kelly, Lanzino, Giuseppe S, Kim, Helen , McCulloch, Charles E. , Hess, Christopher Paul , Hetts, Steven W. , Flemming, Kelly D. , Lanzino, Giuseppe , Lawton, Michael T. , Stefani, Marco Antônio , Salman, Rustam Al‐Shahi

Mayo Clinic

JAMA Neurology | October 6, 2025 | Volume: 82 | Issue: 12 | Pages: 1274

10.1001/jamaneurol.2025.3581 | PMID 41051760 Get It

Importance Annual rates of first intracranial hemorrhage (ICH) from unruptured brain arteriovenous malformations (AVMs) are often quoted as 2% to 4% in clinical practice. Precise estimates and risk factors are unavailable to inform treatment decisions. Objective To provide estimates of rates and risk factors for first ICH in a large cohort study of unruptured brain AVMs. Design, Setting, and Participants The Multicenter Arteriovenous Malformation Research Study (MARS) included data from 9 cohorts, each contributing 100 or more unruptured brain AVMs. The study was conducted from 2017 to 2023 with retrospective and prospective data collection for existing cohorts and/or new recruitment. This was an international study (2 population-based and 7 referral-based cohorts) that included participants diagnosed with an unruptured brain AVM. Exposures Demographic, clinical, and angiographic characteristics. Main Outcome and Measure The primary outcome was time to first ICH after diagnosis of unruptured brain AVM. Data were collected using standardized definitions; missing data were imputed. Cox regression analysis was performed, censoring at first brain AVM treatment, death, or last visit, and allowing baseline hazards to vary by cohort. Results A total of 3225 individuals were eligible for participation in this study. After 195 exclusions, 3030 participants (median [IQR] age, 38 [25-50] years; 1524 female [50.3%]) were included. Among 2989 participants with unruptured brain AVMs, 1333 (45%) presented with seizure. The median (IQR) maximal brain AVM diameter was 3.1 (2.2-4.4) cm, 248 of 2466 AVMs (10%) had exclusively deep venous drainage, 297 of 2690 (11%) were in supratentorial deep or cerebellar locations, and 457 of 2440 (19%) had associated arterial aneurysms. First ICH occurred in 159 participants over 11 339 person-years of follow-up for an ICH rate of 1.40 (95% CI, 1.20-1.64) per 100 person-years. Significant independent risk factors included (1) increasing age category at diagnosis (hazard ratio [HR], 0.87; 95% CI, 0.53-1.41 for those aged 20 to 39 years; HR, 1.23; 95% CI, 0.74-2.04 for those aged 40 to 59 years; and HR, 2.01; 95% CI, 1.14-3.57 for those aged 60 years vs younger than 20 years; P = .008), (2) presence of associated aneurysms (HR, 1.66; 95% CI, 1.06-2.59; P = .03), and (3) cerebellar or supratentorial deep location (HR, 1.87; 95% CI, 1.16-3.00; P = .01). Conclusions and Relevance The annual ICH rate from unruptured brain AVM was lower than that commonly cited in clinical practice. Increasing age, associated arterial aneurysms, and cerebellar or supratentorial deep brain AVM location were associated with risk of first ICH. These results may be used to counsel patients about the natural history of unruptured brain AVMs.
Novel Assessment of Advanced Practice Provider‐Led Head and Neck Cancer Survivorship Clinic: Quality‐of‐Care Metric Analysis and HOUSES Index Application
Wert, K. , May, Byron C. , Janus, Jeffrey R. , Patel, Samip , Pirgousis, Phillip , Zhao, Yujie , Li, Shenduo , Price, Katharine A., McGee, L.A. , Daniel, J. , Kim, Sungjune , Mohammadi, Homan , Wert, Katey , McGee, Lisa A , Ma, Daniel , Routman, David M , Wi, Chung-Ii , Kim, Sungjune , Holtzman, Adam , Patel, Samip N , Janus, Jeffrey R , Routman, David M. , Wi, Chung‐Il , Holtzman, Adam L.

Mayo Clinic

Head & Neck | October 3, 2025 | Volume: 48 | Issue: 2 | Pages: 528-534

10.1002/hed.70062 | PMID 41041809 Get It

ABSTRACT Background As head and neck cancer survival rates improve, there is growing demand for quality survivorship care and tools to predict patient adherence; this study aims to evaluate an advanced practice provider ( APP )‐led survivorship clinic and assess these key metrics. Methods We performed a retrospective review of 213 head and neck cancer patients treated with curative radiation therapy between 2016 and 2023, to assess follow‐up adherence in an advanced practice provider–led survivorship clinic. Results With a median follow‐up of 2.4 years, follow‐up care metrics identified high completion percentages (> 90%) for lung cancer screening, smoking cessation, thyroid screening, dental evaluation, xerostomia, dysphagia, and dysgeusia. The HOUsing ‐based SocioEconomic Status ( HOUSES ) index at diagnosis showed a significant adherence difference (median percentile, 78% vs. 55%, adherent vs. nonadherent; p = 0.03). Conclusions High adherence rates with guideline‐defined care metrics are achievable in an advanced practice provider‐led head and neck cancer survivorship clinic. The HOUSES index may assist in predicting nonadherence; however, further studies are needed.
B-162 Optimizing Thyroid Function Testing: Reducing Unnecessary Orders and Enhancing Patient Care Through Evidence-Based Cascade Algorithms
Terrio, Kim, Dangott, Bryan, Karon, Brad S. , Meroueh, Chady , Mundell, William, Sandleback, Sara, Meroueh, Chady , Sandleback, Sara G.

Mayo Clinic

Clinical Chemistry | October 2, 2025 | Volume: 71 | Issue: Supplement_1 | Pages: No page available

10.1093/clinchem/hvaf086.556 Get It

Abstract Background Thyroid function testing is a common laboratory service that can be optimized by implementing evidence-based algorithms. The thyroid function cascade testing approach at Mayo Clinic Labs is utilized to effectively evaluate and monitor functional thyroid status. The cascade begins with thyroid-stimulating hormone (TSH) as a screening marker. When TSH levels are normal, no additional testing is necessary. When the TSH result is abnormal, appropriate follow-up free T4, total T3, and/or TPO testing will automatically be performed. Providers at our institution can order thyroid function testing with this cascade testing approach or as standalone individual orderable tests. Initial data analysis showed patterns of TSH ordered concurrently with free T4, total T3, and/or anti-TPO. Further analysis revealed that a high number of concurrently ordered tests would not have been necessary had the algorithmic approach been followed. This opportunity for improvement led to the thyroid function testing initiative to direct providers to order the cascade test rather than individual thyroid tests, thereby reducing concurrent and unnecessary testing to improve patient care. Methods The initiative involved creating a new Epic order panel directing providers to order the cascade rather than the individual orderable tests. This intervention is a soft stop that allows providers to proceed by ordering individual tests if desired. We evaluated the impact of the initiative on test utilization, cost savings, and quality indicators using pre- and post-intervention data from all Mayo Clinic sites over a 9-month period. We compared the monthly volumes of concurrent and unnecessary orders of Free T4, Total T3, and TPO before and after the intervention. Concurrent orders were defined as tests collected from the same patient on the same date and time as TSH tests. Unnecessary orders were defined as tests that were outside the reflex range according to the thyroid function ordering algorithm. Cost savings were calculated based on the 2024 CMS reimbursement rates for the associated test CPT® codes. We also monitored and addressed feedback and requests from providers and laboratory staff throughout the initiative. Results The intervention resulted in a 20% average monthly reduction in concurrent orders and an 18% average monthly reduction in unnecessary orders of free T4, total T3, and anti-TPO tests. Estimated savings based on 2024 CMS reimbursement rates are $5,000 monthly and nearly $60,000 annually. Thyroid testing quality was also improved by aligning with clinical guidelines, reducing over-testing, and minimizing the risk of misdiagnosis. Conclusion The thyroid function testing initiative was a successful laboratory stewardship project that reduced redundant testing, improved patient care, and reduced costs. The initiative demonstrated the feasibility and effectiveness of using evidence-based reflex algorithms to optimize laboratory testing. The lessons learned include assessing all tests related to the disease condition to mitigate potential unintended increases in test usage and accounting for patient groups that are not covered by the intended algorithm*s target population. Future directions include expanding the cascade approach to other areas of laboratory medicine, evaluating the long-term outcomes of the initiative, and engaging with providers to ensure the adoption of the initiative.
International, Multispecialty Expert Consensus on Nomenclature for Facial Paralysis
Oyer, Samuel L. , Baptista, Rachel, Boahene, Kofi , Byrne, Patrick J., Chuang, David Chwei‐Chin , Dey, Jacob K. , Diels, Jackie , Hadlock, Tessa A. , Hetzler, Laura , Klebuc, Michael, Labbé, D., Loyo, Myriam , Miller, Matthew Q. , Pepper, Jon‐Paul , Rozen, Shai M. , Snyder‐Warwick, Alison K. , Stephan, Scott J., Tzafetta, Kallirroi , Azizzadeh, Babak , Byrne, Patrick , Dey, Jacob K , Lassaletta, Luis , Loyo, Myriam , Miller, Matthew Q , Pepper, Jon-Paul , Rozen, Shai , Azizzadeh, Babak , Borschel, Gregory Howard , Guerreschi, Pierre , Gur, Eyal , Kim, Jennifer , Mardini, Samir

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | September 30, 2025 | Volume: 27 | Issue: 5 | Pages: 408-415

10.1177/26893614251363957 | PMID 40876002 Get It

Background: Variable terminology is used in the literature to describe facial synkinesis and hypertonicity following incomplete recovery from facial paralysis and its associated medical and surgical treatments. Study Objectives: Establish a nomenclature consensus for this condition among a group of facial nerve experts. Design Type: Consensus study. Methods: Using modified Delphi methodology, an international, multidisciplinary group of facial nerve experts reviewed the terminology for the name of the clinical condition and treatments of interest. Online surveys and a virtual discussion were performed to establish consensus, defined a priori as agreement by 80% of the group. Results: Twenty-five facial nerve experts established consensus after three Delphi rounds. Consensus terminology for the condition is “facial synkinesis” with 84% agreement. Medical treatment is termed “chemodenervation” with 100% agreement. Surgical treatments including “selective facial neurectomy,” “selective facial neurotomy,” “selective facial myectomy,” and “selective facial myotomy,” were defined and reached agreement of 100%. Conclusions: This international group of facial nerve experts has recommended standardized nomenclature for the condition of facial synkinesis and its various treatments. While “facial synkinesis” reached consensus as the preferred term, some experts noted it may insufficiently describe the full clinical spectrum, which includes muscle hypertonicity, weakness, and spontaneous twitching.
CT Colonography Is the More Fit Colorectal Cancer Screening Test
Pietryga, Jason A. , Kim, David H. , Kim, David H

Mayo Clinic

Radiology | September 30, 2025 | Volume: 316 | Issue: 3 | Pages: No page available

10.1148/radiol.252681 | PMID 41025983 Get It

Albumin prevents kidney injury but is underutilized in a cohort of patients undergoing large-volume paracentesis
Rajkumar, Rahul , Duong, Nikki , Kim, W. Ray , Ardiles, Thomas, Coll-Ortega, Cristina , Davis, Elizabeth , Lilley, Jonathan, Zhang, Xuan , Wadhwani, Nisha, Lodaya, Kunal , Viayna, Elisabet , Lilley, Jonathan , Zhang, Xuan , Wadhwani, Nisha , Lodaya, Kunal

Mayo Clinic

Hepatology Communications | September 29, 2025 | Volume: 9 | Issue: 10 | Pages: No page available

10.1097/hc9.0000000000000760 | PMID 41021268 Get It

Background: Cirrhosis and cirrhosis-related deaths have risen in the United States in recent years. Ascites is a common complication, often requiring large-volume paracentesis (LVP). The American Association for the Study of Liver Diseases (AASLD) recommends the administration of albumin in conjunction with LVP to prevent further complications of cirrhosis. Emerging research in cirrhosis care reveals significant variations in outcomes among different demographics. Therefore, we assessed the use of guideline-adherent albumin and outcomes in U.S. patients undergoing LVPs, particularly at the intersection of race, ethnicity, socioeconomic disparities, and cirrhosis. Methods: This retrospective study utilized Cerner Real World Data to identify adults with cirrhosis and ascites undergoing LVP between January 2016 and June 2022. We assessed albumin utilization patterns across racial and ethnic groups and payor types, and their overall impact on acute kidney injury (AKI)-related hospitalization using an adjusted generalized linear model (aGLM). Results: We identified 736 patients: 301 in the LVP + albumin group and 435 in the LVP-only group. Despite clinical recommendations, only 41% undergoing LVPs received albumin. White patients and commercially insured patients received albumin at higher rates (p=0.042 and p=0.009, respectively). The overall rate of AKI-related admissions within the 30-day post-procedure period was 26%. However, patients who received albumin during LVP had a 36% lower risk of short-term AKI-related hospitalization (OR: 0.64; p=0.03). Conclusions: These findings indicate a potential for broader albumin utilization in U.S. patients with refractory ascites undergoing repeated LVPs to reduce AKI-related admissions.
Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits
Shaw, Vikram R. , Byun, Jinyoung , Thrift, Aaron P. , Zhu, Catherine , Li, Donghui , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Knox, J. David, Jalal, Prasun K. , Ghobrial, R. Mark , Nguyen, Mindie H. , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem, Chang, Ping , Chun, Yun Shin , Gu, Jian , Huff, Chad D. , Rashid, Asif, Hwang, Lu‐Yu, Khaderi, Saira, Roberts, Lewis R. , Hassan, Manal M. , Shaw, Vikram R , Byun, Jinyoung , Thrift, Aaron P , Permuth, Jennifer B , Yuan, Jian-Min , Nguyen, Mindie H , Kim, Richard , Gu, Jian , Kaseb, Ahmed O , McGlynn, Katherine A , Roberts, Lewis R , Parikh, Neehar D , Jalal, Prasun K , Han, Younghun , Hatia, Rikita , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Knox, Jennifer, Singal, Amit G. , Kono, Yuko , Shah, Dimpy P. , Kim, Richard D. , El‐Serag, Hashem B. , Rashid, Asif , Klein, Alison P. , McGlynn, Katherine A. , Amos, Christopher I.

Mayo Clinic

International Journal of Cancer | September 27, 2025 | Volume: 158 | Issue: 5 | Pages: 1193-1203

10.1002/ijc.70136 | PMID 41013983 Get It

Abstract Hepatocellular carcinoma (HCC) mortality is increasing globally, partly due to the growing prevalence of nonviral liver diseases. Genome‐wide association studies (GWAS) have identified genetic variants associated with HCC development. Leveraging GWAS summary statistics and linkage disequilibrium score regression (LDSR), we investigated disease co‐development with hepatitis C virus‐negative (HCV‐negative) HCC to provide unique insights into HCC etiology and prioritize relationships for further causal inquiry. We utilized the LDSR statistical framework to estimate the genetic correlation and heritability between HCV‐negative HCC with 901 epidemiologic, behavioral, and clinical traits from the United Kingdom Biobank (UKBB). First, we set the threshold for observed scale heritability of each trait at 0.02 to ensure reliable inferences with adequate study power. Next, we observed significant positive genetic correlations between HCV‐negative HCC and blood‐based biomarkers of liver injury (ALT, GGT) and allostatic load (including glycated hemoglobin, blood pressure, and total albumin). We also identified a positive genetic correlation between HCV‐negative HCC and diseases associated with metabolic dysfunction‐associated steatotic liver disease (MASLD), including diabetes, hypertension, chronic ischemic heart disease, and others. Taken together, our results help to identify polygenic and pleiotropic signals related to different phenotypic traits associated with HCC and support further exploration of the predictive power of blood‐based biomarkers identified in this study for inferring HCC development among HCV‐negative individuals.
Prognostic value of Nectin-4 and Trop2 extracellular vesicles for plasma and urine samples collected from patients with bladder cancer just prior to cystectomy
Bauer, Emily, Thapa, Prabin , Frank, Igor, Shah, Paras , Cheville, John C. , Orme, Jacob J. , Jang, Albert, Kim, Yohan , Lucien, Fabrice

Mayo Clinic

International Journal of Cancer Care and Delivery | September 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129600 Get It